Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows ...

Freenome Holdings, Inc., an early cancer detection company developing blood-based screening tests, and Perceptive Capital Solutions Corp , a special purpose acquisition company (SPAC) sponsored by an ...

As new technology capable of detecting dozens of early-stage cancer types with a single blood test hits the market, support ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows ...

The Columbus Regional Health Lung Institute has been named a Center of Excellence by GO2 for Lung Cancer (GO2) for its ...

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

Criscilla Anderson has died after a seven-year colon cancer battle. She announced her death in a posthumous post, and her ...

ACS--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer ...

Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM ESTCompany ParticipantsDavid Hung - Founder, President, ...

More information can be found at: https://clinicaltrials.gov/study/NCT07227168 .